Insights

More Articles Back to Article

New Darzalex formulation approved in EU for subgroup of MM patients

The European Commission granted extended marketing authorization to Johnson & Johnson's Janssen unit for the new formulation of its triple-drug regimen of Darzalex, or daratumumab, combined with with Celgene's Revlimid, or lenalidomide plus dexamethasone, to treat newly diagnosed patients with multiple myeloma who cannot undergo an autologous stem cell transplant. PMLive (UK) (11/20)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!